Efficacy and Safety of Rifaximin in Treating MAFLD

Clinical trial NCT07185932 · RECRUITING

Trial details

NCT number: NCT07185932
Sponsor: Shanghai Changzheng Hospital
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Metabolic-associated Fatty Liver Disease

Start date: 2024-08-10
Primary completion: 2027-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.